Literature DB >> 33175124

Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome.

Sara Sabeti1, Karen L Ball2, Craig Burkhart3, Lawrence Eichenfield4,5, Esteban Fernandez Faith6,7, Ilona J Frieden8, Roy Geronemus9,10, Deepti Gupta11, Andrew C Krakowski12, Moise L Levy13,14,15, Denise Metry16, J Stuart Nelson17,18, Megha M Tollefson19, Kristen M Kelly1.   

Abstract

Importance: Sturge-Weber syndrome (SWS) is a neurocutaneous syndrome involving the skin, brain, and eyes. Consensus recommendations for management are lacking. Objective: To consolidate the current literature with expert opinion to make recommendations that will guide treatment and referral for patients with port-wine birthmarks (PWBs). Evidence Review: In this consensus statement, 12 nationally peer-recognized experts in dermatology with experience treating patients with SWS were assembled. Key topics and questions were formulated for each group and included risk stratification, optimum treatment strategies, and recommendations regarding light-based therapies. A systematic PubMed search was performed of English-language articles published between December 1, 2008, and December 1, 2018, as well as other pertinent studies identified by the expert panel. Clinical practice guidelines were recommended. Findings: Treatment of PWBs is indicated to minimize the psychosocial impact and diminish nodularity and potentially tissue hypertrophy. Better outcomes may be attained if treatments are started at an earlier age. In the US, pulsed dye laser is the standard for all PWBs regardless of the lesion size, location, or color. When performed by experienced physicians, laser treatment can be safe for patients of all ages. The choice of using general anesthesia in young patients is a complex decision that must be considered on a case-by-case basis. Conclusions and Relevance: These recommendations are intended to help guide clinical practice and decision-making for patients with SWS and those with isolated PWBs and may improve patient outcomes.

Entities:  

Mesh:

Year:  2021        PMID: 33175124      PMCID: PMC8547264          DOI: 10.1001/jamadermatol.2020.4226

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  55 in total

1.  A clinical study of HMME-PDT therapy in Chinese pediatric patients with port-wine stain.

Authors:  Gan Li-Qiang; Wang Hua; Ni Si-Li; Tan Chun-Hua
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-06-08       Impact factor: 3.631

2.  Early Use of Laser for Port-Wine Stains: Timing, Efficacy, and Shared Decision Making.

Authors:  Erin F Mathes; Ilona J Frieden
Journal:  JAMA Dermatol       Date:  2019-04-01       Impact factor: 10.282

Review 3.  Port-Wine Stains: A Focused Review on Their Management.

Authors:  Katelyn Mariko Updyke; Amor Khachemoune
Journal:  J Drugs Dermatol       Date:  2017-11-01       Impact factor: 2.114

4.  A dose-finding study for hemoporfin in photodynamic therapy for port-wine stain: A multicenter randomized double-blind phase IIb trial.

Authors:  Qiuju Wu; Ping Tu; Guoyu Zhou; Huilan Yang; Zhanchao Zhou; Yi Zhao; Qingshan Zheng; Ying Gu; Jining Tao; Xuejun Zhu
Journal:  Photodermatol Photoimmunol Photomed       Date:  2018-04-22       Impact factor: 3.135

5.  Why do port-wine stains (PWS) on the lateral face respond better to pulsed dye laser (PDL) than those located on the central face?

Authors:  Wenxin Yu; Gang Ma; Yajing Qiu; Hui Chen; Yunbo Jin; Xi Yang; Xiaojie Hu; Tianyou Wang; Lei Chang; Henghua Zhou; Wei Li; Xiaoxi Lin
Journal:  J Am Acad Dermatol       Date:  2016-03       Impact factor: 11.527

6.  Flashlamp-pumped pulsed dye laser treatment of port-wine stains.

Authors:  R E Fitzpatrick; N J Lowe; M P Goldman; H Borden; K L Behr; J Ruiz-Esparza
Journal:  J Dermatol Surg Oncol       Date:  1994-11

7.  Prospective study of pulsed dye laser in conjunction with cryogen spray cooling for treatment of port wine stains in Chinese patients.

Authors:  Chun-Hung Chiu; Henry Hin-Lee Chan; Wai-Sun Ho; Chi-Keung Yeung; J Stuart Nelson
Journal:  Dermatol Surg       Date:  2003-09       Impact factor: 3.398

Review 8.  Port wine stain progression: a potential consequence of delayed and inadequate treatment?

Authors:  Kira Minkis; Roy G Geronemus; Elizabeth K Hale
Journal:  Lasers Surg Med       Date:  2009-08       Impact factor: 4.025

Review 9.  The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation.

Authors:  Vi Nguyen; Marcelo Hochman; Martin C Mihm; J Stuart Nelson; Wenbin Tan
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

10.  Outcome with topical sirolimus for port wine stain malformations after unsatisfactory results with pulse dye laser treatment alone.

Authors:  Hebah Mohammadsalam Musalem; Aljoharah Abdulaziz Alshaikh; Lin M Tuleimat; Saad Alajlan
Journal:  Ann Saudi Med       Date:  2018 Sep-Oct       Impact factor: 1.526

View more
  3 in total

1.  A novel somatic mutation in GNAQ in a capillary malformation provides insight into molecular pathogenesis.

Authors:  F Galeffi; D A Snellings; S E Wetzel-Strong; N Kastelic; J Bullock; C J Gallione; P E North; D A Marchuk
Journal:  Angiogenesis       Date:  2022-05-30       Impact factor: 10.658

2.  Whole-Genome Sequencing Identified KCNJ12 and SLC25A5 Mutations in Port-Wine Stains.

Authors:  Kai Chen; Yan-Yan Hu; Lin-Lin Wang; Yun Xia; Qian Jiang; Lan Sun; Shan-Shan Qian; Jin-Zhao Wu; Liu-Qing Chen; Dong-Sheng Li
Journal:  Front Med (Lausanne)       Date:  2022-07-20

3.  Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations.

Authors:  Sara Sabeti; Karen L Ball; Sanjoy K Bhattacharya; Elena Bitrian; Lauren S Blieden; James D Brandt; Craig Burkhart; Harry T Chugani; Stephen J Falchek; Badal G Jain; Csaba Juhasz; Jeffrey A Loeb; Aimee Luat; Anna Pinto; Eric Segal; Jonathan Salvin; Kristen M Kelly
Journal:  Pediatr Neurol       Date:  2021-05-06       Impact factor: 4.210

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.